| 000 | 01748 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517151250.0 | ||
| 264 | 0 | _c20180305 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.15922 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOei, Arlene L | |
| 245 | 0 | 0 |
_aEnhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia. _h[electronic resource] |
| 260 |
_bOncotarget _cApr 2017 |
||
| 300 |
_a28116-28124 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aCell Cycle _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCisplatin _xpharmacology |
| 650 | 0 | 4 |
_aDNA Damage _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFever _xtherapy |
| 650 | 0 | 4 | _aGenes, BRCA1 |
| 650 | 0 | 4 | _aGenes, BRCA2 |
| 650 | 0 | 4 | _aHomologous Recombination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xgenetics |
| 650 | 0 | 4 |
_aPoly(ADP-ribose) Polymerase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aSynthetic Lethal Mutations _xdrug effects |
| 700 | 1 | _avan Leeuwen, Caspar M | |
| 700 | 1 | _aAhire, Vidhula R | |
| 700 | 1 | _aRodermond, Hans M | |
| 700 | 1 | _aTen Cate, Rosemarie | |
| 700 | 1 | _aWestermann, Anneke M | |
| 700 | 1 | _aStalpers, Lukas J A | |
| 700 | 1 | _aCrezee, Johannes | |
| 700 | 1 | _aKok, H Petra | |
| 700 | 1 | _aKrawczyk, Przemek M | |
| 700 | 1 | _aKanaar, Roland | |
| 700 | 1 | _aFranken, Nicolaas A P | |
| 773 | 0 |
_tOncotarget _gvol. 8 _gno. 17 _gp. 28116-28124 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.15922 _zAvailable from publisher's website |
| 999 |
_c27098076 _d27098076 |
||